

2018 BIO International Convention
Personalized Medicine & Diagnostics Track
June 5 – 7, 2018

Opening Plenary: Personalized Medicine, From Concept to Clinic

Time: 11:00 am - noon **Date:** Tuesday, June 5 2018

Speaker: [Raju Kucherlapati](#): Distinguished Paul C. Cabot Professor of Genetics and Medicine, Harvard Medical School; Scientific Director, Harvard-Partners Center for Genetics and Genomics; and Scientific Director of Brigham And Women's Hospital.

Partnerships Power Precision Health: Collaborative Models for Advancing Precision Medicine

Different views on the complexities and the opportunities for transformational innovation and translation of personalized medicine focused on the critical role of collaboration. Panelists will offer examples and ideas for collaboration among multidisciplinary partners to advance the field.

Time: 1:45 – 2:45 pm **Date:** Tuesday, June 5, 2018

Moderator

[Terry Magnuson](#): Professor of Genetics, Vice Chancellor for Research, University of North Carolina School of Medicine

Panelists

[Jill Hagenkord](#): Chief Medical Officer, Color Genomics, Inc.

[Suzanne Belinson](#): Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association

[Stephanie Devaney](#): Deputy Director, All of Us Research Program, National Institutes of Health (NIH).

Improving Health through Focused Screening of Populations

Time: 3:00 – 4:00 pm **Date:** Tuesday June 5, 2018

Better health outcomes, strategies to decrease overall cost of healthcare, and insights coming from basic and translational research are drivers shaping the field of precision medicine. Multi-omic technologies are accelerating the path of discovery, diagnosis and treatment, and are being deployed with large scale clinical utility. In this session we will

present large-scale programs aimed at screening healthy populations for genetic and biochemical risk factors which are actionable.

Moderator

[Philip Empey](#): Associate Director for Pharmacogenomics, Institute for Precision Medicine, University of Pittsburgh.

Panelists

[Shaun Lonergan](#): Vice-President, Corporate Development, Metabolon, Inc.

[Brian Meyer](#): Chairman, Department of Genetics, Research Center, King Faisal Specialist Hospital and Research Centre (KFSHRC)

[Alan Sachs](#): Chief Scientific Officer, Thermo-Fisher Scientific.

[Regulatory Oversight of Personalized Medicine: Today and Tomorrow](#)

A discussion about the evolving status of regulatory oversight of various types of advanced laboratory diagnostics, including LDTs, in vitro testing kits, and NGS-based diagnostic tests. The panel will explore current and evolving policy at FDA, FDA/CMS parallel review, and the Diagnostic Accuracy and Innovation Act (DAIA) legislative proposal.

Time: 11:00 am - noon **Date:** Wednesday June 6, 2018

Moderator

[Cynthia Bens](#): Senior Vice President, Public Policy, Personalized Medicine Coalition

Panelists

[TBD](#): Center for Devices and Radiological Health, Food and Drug Administration (FDA)

[Tamara Syrek-Jensen](#): Director, Coverage & Analysis Group. Centers for Medicare and Medicaid Services (CMS).

[Mark Fleury](#): Principal, Policy Development, Emerging Science at American Cancer Society Cancer Action Network

[Kelli Tanzella](#): Senior Director, Global Regulatory Affairs, Thermo-Fisher Scientific

[Realizing the Potential of Clinical and Consumer Genomics](#)

A discussion about consumer access to inexpensive sequencing technologies from companies that claim to use genetic data for various health-related objectives from personalized training programs to better understanding disease risk. Panelists will explore the business models (B2C vs B2B) and how companies are handling issues around data management, data privacy and ownership.

Time: 1:45 – 2:45 pm **Date:** Wednesday June 6, 2018

Moderator

[Vivek Mittal](#): Partner, Health Advances, LLC

Panelists

[Julie Papanek Grant](#): Partner, Canaan Partners

[Elaine Cheung](#): Vice President, Business Development, MindStrong Health

[Akwasi Asabere](#): Head, Business Development and Partnerships, Helix

Precision Diagnostics: Trends in Evidence Development for Medicare and Commercial Payers

An exploration of trends in payers' evaluation of evidence to support coverage for precision diagnostics, highlighting the growth of the "coverage with evidence development" model of covering tests while collecting additional clinical utility data. Discussion will focus on the Medicare's CED and Palmetto's MoIDX program.

Time: 3:00 – 4:00 pm **Date:** Wednesday June 6, 2018

Moderator

[Brian Carey](#): Partner, Foley Hoag, LLP

Panelists

[Jim Almas](#): Medical Director, MoIDX Program, Palmetto GBA

[Tom McLain](#): Chief Operating Officer, Exosome Diagnostics, Inc.,

[Sean Tunis](#): Founder and Chief Executive Officer Center for Medical Technology Policy

Personalized Medicine in Action: Clinical Implementation at Three Health Care Delivery Institutions

A discussion about three pioneer personalized medicine programs - their strategies, experiences, and successes in achieving and demonstrating value - as examples of the clinical implementation of personalized medicine and the associated benefits to healthcare delivery.

Time: 4:15 – 5:15 pm **Date:** Wednesday June 6, 2018

Moderator

[Daryl Pritchard](#): Senior Vice President, Science Policy at Personalized Medicine Coalition

Panelists

[Thomas Brown](#): Executive Director, Swedish Cancer Institute

[Lincoln Nadauld](#): Executive Director, Intermountain Precision Genomics, Intermountain Healthcare

[James Ford](#): Director, Clinical Genomics, Stanford University

[Is Biotechnology Drowning in Big Data](#)

A discussion about the potential of big data initiatives in healthcare. Has the value of big data been over-promised? How do we separate hype from reality? What can and is being done, and what is simply big data hubris? It seems biotechnology is drowning in its own data—how will it swim?

Time: 9:00 – 10:00 am **Date:** Thursday June 7, 2018

Moderator

[Stephanie Simon](#): Managing Editor, Stat News

Panelists

[Jay Brander](#): President, Novartis Institutes for Biomedical Research, Novartis

[Iya Khalil](#): Chief Commercial Officer, EVP and CO-Founder, GNS Healthcare

[Eric Schadt](#): Chief Executive Officer, Sema4

[Bridging the Gap: Adding Dynamics to the Diagnostic/Therapeutic Interface](#)

An examination of the newest technologies in personalized medicine and how they will fit into the future models of healthcare. Can new technologies utilizing dynamic biomarkers, wearables, bioinformatics and multi-omics help justify the case for new therapeutic strategies or ease the regulatory and reimbursement pathway?

Time: 10:30 – 11:45 am **Date:** Thursday June 7, 2018

Moderator

[Alice Jacobs](#): Advisor, Third Rock Ventures, Entrepreneur in Residence, CalTech

Panelists

[Robbie Barbero](#): Chief Business Officer, Ceres Nanosciences

[Adam Marsh](#): Chief Scientific Officer, Genome Profiling, LLC

[Jennifer Van Eyk](#): Director, Advanced Clinical Biosystems Research Institute. Co-Director Precision Health at Cedars Sinai Medical Center